|
[1]DURAND F,GRAUPERA I,GINES P,et al.Pathogenesis of hepatorenal syndrome:Implications for therapy[J].Am J Kidney Dis,2016,67(2):318-328.
|
|
[2]ANGELI P,LINES P,WONG F,et al.Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J].J Hepatol,2015,62(4):968-974.
|
|
[3]GINES A,ESCORSELL A,LINES P,et al.Incidence,predictive factors,and prognosis of the hepatorenal syndrome in cirrhosis with ascites[J].Gastroenterology,1993,105(1):229-236.
|
|
[4]WONG LP,BLACKLEY MP,ANDREONI KA,et al.Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy[J].Kidney Int,2005,68(1):362-370.
|
|
[5]ALESSANDRIA C,OZDOGAN O,GUEVARA M,et al.MELD score and clinical type predict prognosis in hepatorenal syndrome:Relevance to liver transplantation[J].Hepatology,2005,41(6):1282-1289.
|
|
[6]WIEST R,LAWSON M,GEUKING M.Pathological bacterial translocation in liver cirrhosis[J].J Hepatol,2014,60(1):197-209.
|
|
[7]LU BJ,ZHAO YH,AN YT,et al.Research advances in gut microbiota in liver cirrhosis and related complications[J].J Clin Hepatol,2018,34(11):2433-2437.(in Chinese)鲁冰洁,赵亚红,安泳潼,等.肠道微生物在肝硬化及相关并发症中的研究进展[J].临床肝胆病杂志,2018,34(11):2433-2437.
|
|
[8]WONG F,BLENDIS L.New challenge of hepatorenal syndrome:Prevention and treatment[J].Hepatology,2001,34(6):1242-1251.
|
|
[9]CHEN LL,HAN W,LIU JJ,et al.Research advances in the biomarkers for the early diagnosis of hepatorenal syndrome[J].J Clin Hepatol,2018,34(11):2448-2452.(in Chinese)陈兰兰,韩文,刘京京,等.肝肾综合征早期生物学标志物的研究进展[J].临床肝胆病杂志,2018,34(11):2448-2452.
|
|
[10]GINES P,GUEVARA M,ARROYO V,et al.Hepatorenal syndrome[J].Lancet,2003,362(9398):1819-1827.
|
|
[11]ARROYO V,GINES P,GERBES AL,et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.International Ascites Club[J].Hepatology,1996,23(1):164-176.
|
|
[12]European Association for the Study of the Liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol,2018,69(2):406-460.
|
|
[13]UTAKO P,EMYOO T,ANOTHAISINTAWEE T,et al.Clinical outcomes after liver transplantation for hepatorenal syndrome:A systematic review and meta-analysis[J].Biomed Res Int,2018,2018:5362810.
|
|
[14]BOYER TD,SANYAL AJ,GARCIA-TSAO G,et al.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J].Liver Transpl,2011,17(11):1328-1332.
|
|
[15]SONG T,ROSSLE M,HE F,et al.Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome:A systematic review and meta-analysis[J].Dig Liver Dis,2018,50(4):323-330.
|
|
[16]KELLER F,HEINZE H,JOCHIMSEN F,et al.Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure(including 26 patients with hepatorenal syndrome):The role of hemodialysis[J].Ren Fail,1995,17(2):135-146.
|
|
[17]MANDORFER M,HECKING M.The renaissance of cholemic nephropathy:A likely underestimated cause of renal dysfunction in liver disease[J].Hepatology,2019,69(5):1858-1860.
|
|
[18]ACEVEDO JG,CRAMP ME.Hepatorenal syndrome:Update on diagnosis and therapy[J].World J Hepatol,2017,9(6):293-299.
|
|
[19]BARALDI O,VALENTINI C,DONATI G,et al.Hepatorenal syndrome:Update on diagnosis and treatment[J].World J Nephrol,2015,4(5):511-520.
|
|
[20]NEVENS F,BITTENCOURT PL,COENRAAD MJ,et al.Recommendations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis[J].Dig Dis Sci,2019,64(6):1419-1431.
|
|
[21]GLUUD LL,CHRISTENSEN K,CHRISTENSEN E,et al.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J].Hepatology,2010,51(2):576-584.
|
|
[22]PAPALUCA T,GOW P.Terlipressin:Current and emerging indications in chronic liver disease[J].J Gastroenterol Hepatol,2018,33(3):591-598.
|
|
[23]LENZ K.Noradrenaline in the treatment of patients with hepatorenal syndrome-back to the roots?[J].J Hepatol,2012,57(4):925;author reply 926.
|
|
[24]ARORA V,MAIWALL R,RAJAN V,et al.Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J].Hepatology,2020,71(2):600-610.
|
|
[25]YIN ZA,LIU CS,SUN GX,et al.Cases on national TCM master and professor XIONG Jibo medication thought and experience in the diagnosis and treatment of severe liver diseases[J].J Tradit Chin Med Univ Hunan,2019,39(7):797-800.(in Chinese)尹周安,刘朝圣,孙贵香,等.国医大师熊继柏诊治重症肝病用方思路与经验举隅[J].湖南中医药大学学报,2019,39(7):797-800.
|
|
[26]HE XD,WENG WL,YAO NL.A collection of typical medical cases of contemporary famous old Chinese doctors[M].Beijing:People's Health Publishing House,2009:831-853.(in Chinese)贺兴东,翁维良,姚乃礼.当代名老中医典型医案集[M].北京:人民卫生出版社,2009:831-853.
|
|
[27]YAN HY.A systematic review and Meta-analysis of integrated traditional Chinese and western medicine in the treatment of hepatorenal syndrome[D].Beijing:China Academy of Chinese Medical Sciences,2019.(in Chinese)严海艺.中西医结合治疗肝肾综合征的系统评价及Meta分析[D].北京:中国中医科学院,2019.
|
|
[28]LI NK.The present status of diagnose and treatment on hepatic encephalopathy with integrated Chinese and western medicine[D].Guangzhou:Guangzhou University of Chinese Medicine,2011.(in Chinese)李乃科.肝性脑病的中西医治疗现状及展望[D].广州:广州中医药大学,2011.
|
|
[29]YI GD,TAN J.Protective effects of schisandrin B on rat model of hepatorenal syndrome and its possible mechanism[J].J Med Res,2018,47(9):172-175.(in Chinese)易国栋,谭静.五味子乙素对肝肾综合征大鼠的保护作用及其机制研究[J].医学研究杂志,2018,47(9):172-175.
|
|
[30]Specialty Committee of Digestive Diseases,Chinese Association of Integrative Medicine.Consensus on diagnosis and treatment of ascites due to cirrhosis with integrated traditional Chinese and western medicine[J].Chin J Integr Trad West Med,2011,31(9):1171-1174.(in Chinese)中国中西医结合学会消化疾病专业委员会.肝硬化腹水的中西医结合诊疗共识意见[J].中国中西医结合杂志,2011,31(9):1171-1174.
|
|
[31]CHEN WJ,CHEN YP.Professor Chen Yiping’ s experience in treating hepatorenal syndrome:A case report[J].Shanghai J Trad it Chin Med,2009,43(1):23-24.(in Chinese)陈万佳,陈以平.陈以平辨治肝肾综合征验案1则[J].上海中医药杂志,2009,43(1):23-24.
|
|
[32]CHEN HX,ZHANG ZZ,WU SQ,et al.Effect of gastrointestinal formula plus or minus combined with terlipressin on relevant parameters in patients with cirrhotic ascites and typeⅡhepatorenal syndrome[J].Zhejiang J Tradit Chin Med,2019,54(3):169-170.(in Chinese)陈红星,张志忠,吴世泉,等.胃苓散加减方联合特利加压素对肝硬化腹水合并Ⅱ型肝肾综合征患者相关指标的影响[J].浙江中医杂志,2019,54(3):169-170.
|
|
[33]CHAI M,YAO Y,CAO YJ,et al.Clinical study on treatment of refractory ascites of hepatorenal syndrome with Zhenwu decoction combined with Fangji Fuling decoction plus ascites ultra filtration treatment[J].J Liaoning Univ Tradit Chin Med,2019,21(9):192-195.(in Chinese)柴梅,姚耀,曹玉鹃,等.真武汤合防己茯苓汤加减联合腹水超滤浓缩回输治疗肝肾综合征顽固性腹水临床研究[J].辽宁中医药大学学报,2019,21(9):192-195.
|
|
[34]QU ZW,YU MJ,FENG L,et al.Clinical researches of hepatorenal syndrome treated with methods of reinforcing kidney and strengthening spleen[J].J Beihua Univ(Nat Sci),2019,20(1):99-102.(in Chinese)曲智威,于明俊,冯雷,等.补肾健脾法治疗肝肾综合征临床研究[J].北华大学学报(自然科学版),2019,20(1):99-102.
|
|
[35]ZOU YQ,WANG YS,ZHU J,et al.Discuss on symptom and treatment of kidney diseases with traditional Chinese medicine in the Yellow Emperor’s Inner Classic[J].J Nangjing Univ Tradit Chin Med,2019,35(5):513-517.(in Chinese)邹燕勤,王铀生,朱俊,等.《内经》所蕴含的中医肾病证治思路探讨[J].南京中医药大学学报,2019,35(5):513-517.
|
|
[36]CUI ZL,FU Q,JIANG M,et al.Professor LIU Renhe's experiences on treating chronic kidney disease from liver theory[J].Liaoning J Tradit Chin Med,2019,46(4):698-700.(in Chinese)崔赵丽,傅强,姜淼,等.国医大师吕仁和从肝论治慢性肾脏病经验探微[J].辽宁中医杂志,2019,46(4):698-700.
|
|
[37]PAN Y,WANG YJ.Zhang Qi's experience in the treatment of cirrhosis and ascites[J].J Tradit Chin Med,2011,52(5):380-381.(in Chinese)潘洋,王炎杰.张琪治疗肝硬化腹水经验[J].中医杂志,2011,52(5):380-381.
|
|
[38]ZHAO ZL,KANG HY,ZHANG Z,et al.Effectiveness of Tan Hong Injection combined with terlipressin in the treatment of heavy hepatitis with type 2 hepatorenal syndrome[J].Mod J Integr Tradit Chin West Med,2018,27(15):1637-1640.(in Chinese)赵子龙,康海燕,张志,等.丹红注射液联合特利加压素治疗重型肝炎合并2型肝肾综合征疗效观察[J].现代中西医结合杂志,2018,27(15):1637-1640.
|
|
[39]YAO Y,CHAI M,CAO YJ,et al.Effect of No.1 decotion of liver cirrhosis ascites combined with ascites reinfusion method for refractory ascites due to cirrhosis with type II hepatorenal syndrome[J].J Sichuan Tradit Chin Med,2018,36(8):87-89.(in Chinese)姚耀,柴梅,曹玉娟,等.肝硬化腹水1号汤联合腹水超滤量回输法对难治性肝硬化腹水伴Ⅱ型肝肾综合征的影响[J].四川中医,2018,36(8):87-89.
|
|
[40]PENG T,HU Z.Study on offect of enema with traditional medicine for chronic renal failure[J].Jiangxi Med J,2005,40(3):130-131.(in Chinese)彭涛,胡昭.中药灌肠在慢性肾衰竭中的治疗作用[J].江西医药,2005,40(3):130-131.
|
|
[41]CHEN WH,LI WY,DENG DF.Observation of terlipressin with retention-enema of traditional Chinese drug in management of patients with hep-atorenal syndrome[J].J Clin Hepatol,2008,24(5):351-353.(in Chinese)陈维华,李文勇,邓代富.特利加压素联合中药泻心汤保留灌肠治疗肝硬化肝肾综合征的疗效观察[J].临床肝胆病杂志,2008,24(5):351-353.
|
|
[42]PANG GH.Clinical effects of plasma replacement combined with rhubarb enema for the treatment of heavy hepatitis and hepatorenal syndrome[J].China Prac Med,2016,11(6):201-202.(in Chinese)庞国宏.血浆置换联合大黄灌肠治疗重型肝炎并肝肾综合征的临床效果[J].中国实用医药,2016,11(6):201-202.
|
|
[43]ZHU CQ,CHEN EJ.Treatment of hepatorenal syndrome with acupuncture point compresses and Octreotide static drops in27 clinical cases[J].Jiangsu J Tradit Chin Med,2012,44(11):66-67.(in Chinese)朱长权,陈二军.中药穴位外敷联合奥曲肽静滴治疗肝肾综合征27例临床研究[J].江苏中医药,2012,44(11):66-67.
|
DownLoad: